XML 63 R38.htm IDEA: XBRL DOCUMENT v3.25.4
LICENSE, COLLABORATION AND OTHER REVENUE (Tables)
 12 Months Ended
Dec. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Revenues Recognized from License, Collaboration and Other Significant Agreements
The Company recognized the following revenues from its license, collaboration and other revenue agreements (in thousands):
Years Ended December 31,
EntityDescription202520242023
MediceLicense and Product Supply of Vafseo in EU$411 $22 $10,968 
TPC, formerly known as Mitsubishi Tanabe PharmaLicense and Product Supply of Vafseo in Japan2,794 2,612 5,735 
JT and ToriiLicense and royalties related to the sale of Riona in Japan5,659 5,366 5,394 
Otsuka Terminated U.S. and International Agreements— — 2,225 
Total License, Collaboration and Other Revenue$8,864 $8,000 $24,322 
Schedule of Changes in Contract Assets and Liabilities
The following table presents changes in the Company’s contract assets and liabilities related to the Company's sales to its AG Distributor (in thousands):
Year Ended December 31, 2025
Balance at
Beginning of
Period		AdditionsDeductionsBalance at End
of Period
Contract assets:
Accounts receivable$— $12,006 $(11,812)$194 
Contract liabilities:
Deferred revenue$— $10,675 $(7,994)$2,681 
The following table presents changes in the Company’s contract assets and liabilities related to license, collaboration and other revenue agreements (in thousands):
Year Ended December 31, 2025
 Balance at
Beginning of
Period		AdditionsDeductionsBalance at End
of Period
Contract assets:    
Accounts receivable(1)
$2,010 $8,894 $(8,513)$2,391 
Contract liability:
Deferred revenue $— $— $— $— 
Year Ended December 31, 2024
Balance at
Beginning of
Period		AdditionsDeductionsBalance at End
of Period
Contract assets:
Accounts receivable(1)
$3,333 $8,562 $(9,885)$2,010 
Contract liabilities:
Deferred revenue (long-term)(2)
$43,296 $— $(43,296)$— 
(1)Excludes accounts receivable from product sales of Auryxia and Vafseo which are included in the accompanying consolidated balance sheets as of December 31, 2025 and 2024. 
(2)See Note 8, Liability Related to Settlement Royalties, Working Capital Fund Liability and Liability Related to Sale of Future Royalties, for further information.
Schedule of Revenue Recognized Resulting from Changes in Contract Assets and Contract Liabilities
During the years ended December 31, 2025, 2024 and 2023, the Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the respective periods (in thousands):
 Years Ended December 31,
Revenue Recognized in the Period from:202520242023
Deferred revenue - beginning of the period$— $— $3,738